T. Rowe Price Associates
CLYM

T. Rowe Price Associates’s Climb Bio CLYM Stock Holding History

T. Rowe Price Associates’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.1M Sell
1,916,968
-6,671
-0.3% -$38.5K ﹤0.01% 1148
2025
Q4 		$7.7M Buy
1,923,639
+1,396,722
+265% +$3.35M ﹤0.01% 1289
2025
Q3 		$1.06M Sell
526,917
-21,048
-4% -$39.1K ﹤0.01% 2039
2025
Q2 		$680K Sell
547,965
-37,763
-6% -$47K ﹤0.01% 2157
2025
Q1 		$716K Sell
585,728
-42,922
-7% -$69.6K ﹤0.01% 2112
2024
Q4 		$1.13M Sell
628,650
-43,916
-7% -$159K ﹤0.01% 1912
2024
Q3 		$3.42M Buy
+672,566
New +$4.76M ﹤0.01% 1414

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

T. Rowe Price Associates's CLYM Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Climb Bio (CLYM) stake by 0.35% in Q1 2026, selling an estimated $38.5K and leaving 1,916,968 shares worth $13.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1148.

T. Rowe Price Associates first reported a position in CLYM in Q3 2024 and has held it in 7 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • T. Rowe Price Associates held 1,916,968 shares of Climb Bio worth $13.1M as of Q1 2026.
  • T. Rowe Price Associates sold 6,671 Climb Bio shares in Q1 2026, an estimated $38.5K.
  • Climb Bio made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1148 holding.
  • T. Rowe Price Associates first reported a position in Climb Bio in Q3 2024 and has held it in 7 quarters since.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.